Leebeek F W G, Smalberg J H, Janssen H L A
Department of Haematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Neth J Med. 2012 Nov;70(9):400-5.
Abdominal vein thrombosis is a rare, but potentially life-threatening form of venous thrombosis. It mainly involves the hepatic veins (Budd Chiari syndrome, BCS), portal veins (PVT) and mesenteric veins. In recent years several large-scale studies have been performed to study the underlying aetiological factors in these thrombotic disorders. Both inherited and acquired thrombophilia factors are frequently observed in these patients. Factor V Leiden mutation is frequently found in patients with BCS and prothrombin gene variant is seen more frequently in PVT. Myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythemia, are underlying disorders in 30-40% of patients with abdominal vein thrombosis. Other aetiological factors are paroxysmal nocturnal haemoglobinuria (PNH), autoimmune disorders and hormonal factors. Recently, several new risk factors have been reported and are discussed in this review. BCS and PVT are multi-factorial disorders. In nearly 50% of patients two, and in 16% even three prothrombotic risk factors were found at presentation. Because patients with abdominal vein thrombosis have a high risk of recurrence immediate anticoagulant treatment is necessary. The duration of treatment is still a matter of debate because these patients also have a high risk of bleeding, especially those with portal hypertension. For BCS patients life-long anticoagulant treatment is advised. In patients with PVT it is recommended to tailor treatment to the individual patient based on the presence of an underlying prothrombotic disorder and the risk of bleeding.
腹部静脉血栓形成是一种罕见但可能危及生命的静脉血栓形成形式。它主要累及肝静脉(布加综合征,BCS)、门静脉(PVT)和肠系膜静脉。近年来,已经进行了几项大规模研究来探讨这些血栓形成性疾病的潜在病因。在这些患者中,遗传性和获得性血栓形成倾向因素都很常见。因子V莱顿突变在BCS患者中经常发现,而凝血酶原基因变异在PVT患者中更常见。骨髓增殖性肿瘤(MPN),包括真性红细胞增多症和原发性血小板增多症,是30-40%的腹部静脉血栓形成患者的潜在疾病。其他病因包括阵发性夜间血红蛋白尿(PNH)、自身免疫性疾病和激素因素。最近,有几个新的危险因素被报道,并在本综述中进行了讨论。BCS和PVT是多因素疾病。在近50%的患者中发现了两种促血栓形成危险因素,甚至在16%的患者中发现了三种。由于腹部静脉血栓形成患者有很高的复发风险,因此立即进行抗凝治疗是必要的。治疗持续时间仍存在争议,因为这些患者也有很高的出血风险,尤其是那些患有门静脉高压的患者。对于BCS患者,建议进行终身抗凝治疗。对于PVT患者,建议根据潜在的促血栓形成疾病的存在和出血风险为个体患者量身定制治疗方案。